Oceania Healthcare (OCA) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
Meeting held in person and online, enabling shareholder participation and electronic voting.
Chair introduced board members, executive team, legal advisors, and auditors.
Quorum confirmed, meeting properly convened, and notice of meeting duly given.
Voting procedures and Q&A protocols explained for both in-person and virtual attendees.
Meeting opened with addresses from the Chair and CEO, followed by business and agenda matters.
Financial performance review
Total assets have tripled since 2017, reaching nearly NZD 3 billion.
New sales volumes increased by over 17% and resales up 5% in FY25.
Occupancy at The Helier rose from 14% to 41% by May 2025; Bellevue apartments nearly fully sold within 18 months.
Unsold stock reduced from $353m to $342m despite $120m of new stock added; total sales reached $131m.
Gearing improved to 36.3% from 38.3% last year; NZD 97 million in unused debt capacity.
Board and executive committee updates
Board comprises experienced directors with diverse skills in climate, markets, relationships, growth, and property.
Board actively involved through site visits and health and safety walks.
Rob Hamilton stood for re-election as director, supported by the board.
Board holds discretionary proxy votes and oversees risk management.
Executive team includes CEO, CFO, Chief Legal Officer, and leaders in sales, customer service, clinical care, and property.
Latest events from Oceania Healthcare
- Record results, cost discipline, and strategic focus on growth and risk management defined the AGM.OCA
AGM 2026 - Secured bond offer funds growth and debt reduction, with record FY26 results and strong sustainability.OCA
Investor presentation - Record sales, EBITDA growth, and debt reduction position for positive cash flow in FY27.OCA
H2 2026 - Underlying EBITDA up 19%, gearing at 34.8%, and strong sales drive improved results.OCA
H1 2026 - Disciplined execution and service innovation drive sustainable growth and returns to FY31.OCA
Investor Day 2025 Presentation - Underlying EBITDA rose 4.1% as sales volumes and operational efficiency both improved.OCA
Investor Presentation - EBITDA up, cash flow strong, but net profit down; sales and debt reduction remain key priorities.OCA
H1 2025 - Strong financial growth, reinvestment, and innovation highlighted at the AGM.OCA
AGM 2024 - EBITDA up 4.1%, sales volumes up 9.2%, and cost savings of up to $20m targeted.OCA
H2 2025